Want to see AU:IMM full AI Analyst Report?
IMM Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.47
Previous CloseN/A
Volume4.97M
Average Volume (3M)12.91M
Market Cap
AU$33.90M
Enterprise ValueAU$10.28M
Total Cash (Recent Filing)AU$68.87M
Total Debt (Recent Filing)AU$1.05M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Feb 25, 2027EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding1,474,110,200
10 Day Avg. Volume6,221,202
30 Day Avg. Volume12,911,994
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.27
Price to Sales (P/S)5.36
P/FCF Ratio-1.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.07Price Target Upside40.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$3.89M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sharp FY2026 revenue increase and generally positive multi-year growth indicate improving traction for the company’s partnered biotechnology programs. Sustained top-line expansion could increase funding capacity, support further development, and strengthen the commercial relevance of its LAG-3 platform over coming quarters.
Gross Margin ImprovementAn approximately 83% gross margin represents a substantial improvement in the economics of reported revenue and suggests that the revenue mix can support meaningful gross profit. If maintained, this provides a stronger foundation for absorbing operating costs as the company advances its clinical and partnered programs.
Low Debt BurdenVery low debt limits interest expense and reduces balance-sheet pressure compared with a highly leveraged development company. Positive equity of approximately $61.5M also provides a capital buffer, allowing more financial flexibility while Immutep funds clinical development and seeks to improve operating performance.
Bears Say
Persistent Net LossesThe large net loss shows that improved revenue and gross margin have not yet translated into sustainable profitability. Deeply negative operating margins indicate substantial ongoing expense intensity, leaving the company dependent on future revenue growth, partnerships, or external capital to fund its development plans.
Cash BurnMaterially negative operating and free cash flow demonstrate that the business remains significantly cash consumptive despite its improved revenue profile. Continued burn can restrict investment flexibility and require additional funding before operating scale improves, making cash conversion a central medium-term execution challenge.
Equity ErosionThe substantial decline in equity signals that ongoing losses or capital structure changes have reduced the company’s financial buffer. If losses persist, Immutep may face greater reliance on external financing, while potential dilution could limit existing shareholders’ participation in future value creation.
Immutep Ltd News
IMM FAQ
What was Immutep Ltd’s price range in the past 12 months?
Immutep Ltd lowest share price was AU$0.02 and its highest was AU$0.47 in the past 12 months.
What is Immutep Ltd’s market cap?
Immutep Ltd’s market cap is AU$33.90M.
When is Immutep Ltd’s upcoming earnings report date?
Immutep Ltd’s upcoming earnings report date is Feb 25, 2027 which is in 121 days.
How were Immutep Ltd’s earnings last quarter?
Immutep Ltd released its earnings results on Sep 02, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of -AU$0.004 by -AU$0.019.
Is Immutep Ltd overvalued?
According to Wall Street analysts Immutep Ltd’s price is currently Undervalued.
Does Immutep Ltd pay dividends?
Immutep Ltd does not currently pay dividends.
What is Immutep Ltd’s EPS estimate?
Immutep Ltd’s EPS estimate is -0.01.
How many shares outstanding does Immutep Ltd have?
Immutep Ltd has 1,474,110,200 shares outstanding.
What happened to Immutep Ltd’s price movement after its last earnings report?
Immutep Ltd reported an EPS of -AU$0.023 in its last earnings report, missing expectations of -AU$0.004. Following the earnings report the stock price went down -3.922%.
Which hedge fund is a major shareholder of Immutep Ltd?
Currently, no hedge funds are holding shares in AU:IMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.07 (40.00% Upside)
AU$0.07 (40.00% Upside)
Blogger Sentiment
Bullish
AU:IMM Sentiment 96%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.75%
12-Months-Change
Fundamentals
Return on Equity
-98.86%
Trailing 12-Months
Asset Growth
-43.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
IMM Stock 12 Month Forecast
Average Price Target
AU$0.07
▲(40.00% Upside)
Technical Analysis
Imugene
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Radiopharm Theranostics Limited
―